Mark Hillen

Categories: | | | | | | |
Second-generation sub400 cross-linking for ultra-thin keratoconus corneas published
ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.

READ

PACK-CXL for infectious keratitis
Categories: | | |
ELZA researchers publish practical review of PACK-CXL for infectious keratitis
A new ELZA review in Die Ophthalmologie examines the mechanisms, clinical evidence, protocol selection, and indications for PACK-CXL in infectious keratitis.

READ

Second global consensus on keratoconus and ectatic disease
Categories: | | |
ELZA and the Second Global Consensus on Keratoconus and Ectatic Diseases
The Second Global Consensus on Keratoconus and Ectatic Diseases was published today, and ELZA played a key role in its development.

READ

Categories: | | |
High-dose riboflavin and sunlight CXL?
Can sunlight and riboflavin (vitamin B2) treat keratoconus? New publication explains why current evidence does not support it.

READ

Categories: | | |
ELZA and the Ocular Biome
“The eye, once thought sterile and immunoprivileged, is entangled in systemic crosstalk between microbial tenants and ocular health.”

READ

Progress in Retina and Eye Research Cover Image - CXL REVIEW
Categories: | | | | | |
Making an Impact: Prog Ret Eye Res CXL Review
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.

READ

.
.